Month: July 2012

ThromboGenics says FDA accepts Ocriplasmin filing

Your Health Matters

BRUSSELS (Reuters) – Drug developer ThromboGenics NV said on Tuesday that U.S. regulators have accepted its request for approval of its main drug, and granted it priority status, meaning it could be ready for sale in six months. ThromboGenics licensed the eye drug ocriplasmin in March to Novartis’s opthalmic division to sell outside the United States, but it plans to market the product itself in the U.S. (Reporting By Ben Deighton; editing by Justyna Pawlak)

,

Pharming sells U.S. cattle facilities

Your Health Matters

BRUSSELS (Reuters) – Biotechnology company Pharming said on Tuesday it has sold its U.S. cattle facilities to Sexing Technologies, a private company based in Texas, as the cash-strapped Dutch company focuses on its rabbit operations. The company, which makes drugs in the milk of genetically modified rabbits, said last month it may put itself up for sale and could issue shares to raise cash. It did not say how much it was paid for the U.S. facilities. (Reporting by Ben Deighton; Editing by Clarence Fernandez)

GlaxoSmithKline settles healthcare fraud case for $3 billion

Your Health Matters

A GlaxoSmithKline logo is seen outside one of its buildings in west London, ahead of company resultsWASHINGTON (Reuters) – GlaxoSmithKline Plc agreed to plead guilty to misdemeanor criminal charges and pay $3 billion to settle what government officials on Monday described as the largest case of healthcare fraud in U.S. history. The agreement, which still needs court approval, would resolve allegations that the British drugmaker broke U.S. laws in the marketing and development of pharmaceuticals. …

1 … 112 113 114 115 116 … 121